fospropofol disodium
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Colonoscopy
Conditions
Colonoscopy, Colon Polyps
Trial Timeline
Sep 1, 2004 → Dec 1, 2004
NCT ID
NCT00209573About fospropofol disodium
fospropofol disodium is a phase 3 stage product being developed by Eisai for Colonoscopy. The current trial status is completed. This product is registered under clinical trial identifier NCT00209573. Target conditions include Colonoscopy, Colon Polyps.
What happened to similar drugs?
1 of 1 similar drugs in Colonoscopy were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00209599 | Phase 2 | Terminated |
| NCT00209560 | Phase 3 | Terminated |
| NCT00209573 | Phase 3 | Completed |
| NCT00209586 | Phase 3 | Terminated |
| NCT00209547 | Phase 3 | Completed |
| NCT00209534 | Phase 2 | Completed |
Competing Products
7 competing products in Colonoscopy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl | Eisai | Phase 2/3 | 38 |
| fospropofol disodium | Eisai | Phase 2 | 27 |
| fospropofol disodium | Eisai | Phase 2 | 35 |
| HSK3486 + Propofol | Haisco Pharmaceutical Group | Phase 2 | 35 |
| HSK3486 + Propofol | Haisco Pharmaceutical Group | Phase 2 | 35 |
| Methylene Blue MMX 25 mg modified release tablets | Cosmo Pharmaceuticals | Phase 2 | 29 |
| Polyethylene glycol 4000 + Macrogol 3350 plus ascorbic acid | Rafael Holdings | Approved | 33 |